RecruitingPhase 2NCT06031688Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Sponsor: SWOG Cancer Research NetworkJonesboro, AR · Little Rock, AR · +276 more sites
RecruitingPhase 3NCT06357533Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsSponsor: AstraZenecaLittle Rock, AR · Springdale, AR · +61 more sites
RecruitingPhase 2NCT05642572Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Sponsor: SWOG Cancer Research NetworkJonesboro, AR · Little Rock, AR · +452 more sites
RecruitingPhase 2 / Phase 3NCT03851445Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerSponsor: SWOG Cancer Research NetworkJonesboro, AR · Little Rock, AR · +1227 more sites
RecruitingPhase 2NCT04079179Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersSponsor: Carl AllenLittle Rock, AR · +11 more sites